Shocking 40% growth by JAZZ narcolepsy drug
Jazz Pharmaceutical's 2012 outlook tops forecasts
THE narcolepsy drug Xyrem should grow at least 40 percent for the year.
PALO ALTO, Calif. (AP) -- Jazz Pharmaceuticals Inc. said Thursday it expects a larger profit in 2012 after it completes its acquisition of Azur Pharma Ltd., and said sales of its narcolepsy drug Xyrem should grow at least 40 percent for the year.
Jazz Pharmaceuticals said it expects to report an annual profit of $2.62 to
$2.88 per share, or $4 to $4.15 per share excluding one-time costs and gains.
The company forecast $465 million to $490 million in revenue, including $330
million to $340 million in sales of Xyrem. It expects $460 million to $485
million in total product sales.
Analysts expect the combined company to earn $3.37 per share on revenue of
$455.8 million, according to FactSet.